Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-102393
Filing Date
2025-08-05
Accepted
2025-08-05 07:14:07
Documents
81
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q beam-20250630.htm   iXBRL 10-Q 2788283
2 EX-10.1 beam-ex10_1.htm EX-10.1 23720
3 EX-31.1 beam-ex31_1.htm EX-31.1 19372
4 EX-31.2 beam-ex31_2.htm EX-31.2 29442
5 EX-32.1 beam-ex32_1.htm EX-32.1 11510
6 EX-32.2 beam-ex32_2.htm EX-32.2 10628
  Complete submission text file 0000950170-25-102393.txt   11513126

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT beam-20250630.xsd EX-101.SCH 1395345
84 EXTRACTED XBRL INSTANCE DOCUMENT beam-20250630_htm.xml XML 2510913
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 857-327-8775
Beam Therapeutics Inc. (Filer) CIK: 0001745999 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)